The global race to develop so-called “double G” and “triple G” agonists is heating up to boost the efficacy of…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Daiichi Sankyo Earnings Lower on Yen Moves; Olmesartan Suffers 21.8% Slide
November 1, 2016
-
BUSINESS Takeda’s Half-Year Sales Slip on LLP Transfer, but Profits Zoom
October 31, 2016
-
BUSINESS Public “IP Platforms” Necessary for Startups: IPSN President
October 28, 2016
-
ORGANIZATION Realtor-Led Tokyo Life Sciences Hub Initiative Aims to Fill Void between Academia, Pharmas
October 27, 2016
-
BUSINESS AZ Japan Sees Combo Holding Promise in Immuno-Oncology Race, Set to Triple Oncology Sales in 5 Years
October 26, 2016
-
BUSINESS Wholesalers Hails Gilead Ambition to Unearth More Hep C Patients through Collaboration
October 26, 2016
-
BUSINESS Ono Files Patent Infringement Suit over Keytruda
October 25, 2016
-
REGULATORY Keytruda’s November Listing Skip Likely amid Opdivo Re-Pricing Fuss
October 24, 2016
-
BUSINESS Kipres Generics Might Add Bronchial Asthma Indication before December Listing
October 21, 2016
-
BUSINESS Kaketsuken’s Biz Transfer Talks Fall Apart, but Minister Nixes Its Continued Operations
October 20, 2016
-
BUSINESS Astellas Calls Off Biz Transfer Talks with Kaketsuken
October 19, 2016
-
REGULATORY Urgent Need for Rule on Interim NHI Price Revisions; Current System Unable to Respond in Case of Add’l Indications: MOF Budget Examiner
October 19, 2016
-
TRENDS Gilead Stays Pat on Hep C Plan, Japan Chief Says Innovation Outstrips Re-Pricing Hit
October 18, 2016
-
REGULATORY Govt Panel Member Pushes 50%-Plus Cut for Opdivo Price
October 17, 2016
-
BUSINESS Gilead Japan Trying to Dig Up Untreated Hep C Patients as Demand Ebbs
October 14, 2016
-
BUSINESS Takeda to Tighten R&D Focus, Strengthen Collaboration with Outside Parties; Main Challenge Will Be Financial
October 13, 2016
-
BUSINESS Interview: Teva Exec Says Takeda JV Can Grow Profit despite Generic Price Declines
October 12, 2016
-
BUSINESS Teva-Takeda JV Eyes Top Spot in Off-Patent Drug Market: CEO
October 11, 2016
-
ACADEMIA Osteoporosis Experts Express “Shock” at Discontinuation of Development of Odanacatib
October 7, 2016
-
REGULATORY Chuikyo OKs Application of Huge-Seller Re-Pricing to Opdivo; Payers Loath to Use Ono Sales Outlook for Calculation
October 6, 2016
ページ
1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…